topotecan has been researched along with ponatinib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Ambudkar, SV; Baer, MR; Bhullar, J; Cai, L; Chen, ZS; Fang, HB; Natarajan, K; Sen, R; Shukla, S | 1 |
2 other study(ies) available for topotecan and ponatinib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carbocyanines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chlorophyll; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imidazoles; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Protein Binding; Pyridazines; Rhodamine 123; Topotecan | 2012 |